Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
211 Leser
Artikel bewerten:
(1)

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary - a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in Japan, the company has grown from a small team with a bold vision into a global organization supporting clinical trials in more than 30 countries.

Linical 20 Year Anniversary Logo

From the beginning, Linical set out to do more than manage clinical studies - the company set out to make a meaningful impact on patients' lives. Over the years, Linical's services have expanded to include full-service clinical trial management, site selection and feasibility, regulatory support, biometrics, pharmacovigilance, and drug development strategies. Throughout this growth, Linical's core mission has remained the same: to advance science while prioritizing patient safety and wellbeing.

"What began as a small startup with a few dedicated professionals from the pharmaceutical industry has grown into a global force in clinical research," said Kazuhiro Hatano, President and CEO of Linical. "We've never lost sight of the fact that at the heart of every clinical trial is a patient who is hoping for a better future. That's what continues to drive us."

Over the past two decades, Linical has supported hundreds of clinical studies across a range of therapeutic areas including oncology, neurology, immunology, and rare diseases. By leveraging technology and data-driven processes, the company has delivered faster study start-up times, improved site performance, and enhanced trial quality. Its investments in decentralized trial capabilities and digital tools have positioned the company at the forefront of innovation, especially in an era where flexibility and accessibility in research are more critical than ever.

The company attributes its success to a collaborative culture, strong partnerships with sponsors and sites, and an unwavering focus on patients. "Clinical research is ultimately about people," added Mr. Hatano. "It's about the people participating in trials, the investigators treating them, and the sponsors developing new therapies. We're proud to be part of that ecosystem, helping turn scientific discovery into real-world impact."

As it marks its 20th year, Linical is also looking ahead. The arrival of artificial intelligence is transforming the clinical research industry. With continued investment in global operations, advanced analytics, and patient-focused technologies, the company plans to further strengthen its ability to deliver efficient, high-quality clinical trials that bring new treatments to market faster.

"We're proud of what we've achieved, but we're even more excited about the future," said Mr. Hatano. "Our work is far from done, and we remain committed to our purpose: improving lives through research."

About Linical:
Linical is a global provider of clinical research services, supporting biopharmaceutical companies in bringing innovative therapies to patients across APAC, Europe, and North America. With a focus on quality, technology, and patient wellbeing, Linical delivers tailored solutions for clinical trials across all phases and numerous therapeutic areas.

Linical Celebrates 20 Year Anniversary

Logo - https://mma.prnewswire.com/media/2704683/Linical_20_Year_Anniversary_Logo.jpg

Photo - https://mma.prnewswire.com/media/2704684/Linical_PR_Newswire_20th_Anniversary.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/linical-celebrates-20-years-of-advancing-clinical-research-and-patient-wellbeing-302474796.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.